11 completed, 5 terminated, 5 unknown, 3 withdrawn. 10 Phase 2, 9 Phase 1, 4 Not applicable, 3 Phase 3, 2 Phase 4.
Follow Hepatoma: new trials by email Literature Review of Hepatoma trials Research Report on Hepatoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. MDN-001 Injection(Yttrium-90 Microsphere Injection) - Hepatoma, Unresectable Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Suzhou Mednovo Yi Medical Technology Co., Ltd. | 40 | 2025-08-04 | 2026-02-06 |
| The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/CT and Enhanced MRI in Hepatic Malignancies PET scan of FDG - Hepatoma | Not yet recruiting | Shanghai East Hospital | 60 | 2024-12-01 | 2024-11-22 | |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Nivolumab, Relatlimab - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Completed | Bristol-Myers Squibb | 266 | 2021-02-04 | 2026-01-08 |
| Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery Thoracic continuous epidural analgesia - Hepatoma, Pancreas Cancer | Not applicable | Completed | Mahidol University | 140 | 2020-10-22 | 2023-08-23 |
| Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma Regorafenib/Nivolumab - Carcinoma, Hepatocellular, Hepatoma | Phase 2 | Completed | Asan Medical Center | 42 | 2020-06-16 | 2022-12-06 |
| HepATocellular Cancer Hcv Therapy Study Elbasvir / Grazoprevir Oral Tablet - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Withdrawn | Bayside Health | 2019-09-01 | 2020-09-14 | |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies CAR-T/TCR-T cells immunotherapy - Esophagus Cancer, Hepatoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 50 | 2019-09-01 | 2021-02-04 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies CAR-T cell immunotherapy - B-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 73 | 2018-03-01 | 2019-12-11 |
| TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma Transarterial embolization, Microwave Ablation - Hepatocellular Carcinoma, Hepatoma | Not applicable | Terminated | Wake Forest University Health Sciences | 8 | 2016-03-01 | 2022-04-22 |
| A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma DEB-TACE, Sorafenib - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Terminated | Boston Scientific Corporation | 2 | 2015-11-01 | 2021-02-12 |
| Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Sevoflurane, Desflurane - Hepatocellular Carcinoma, Hepatoma | Phase 4 | Withdrawn | Tokyo Medical and Dental University | 2014-07-01 | 2023-05-03 | |
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma TKM-080301 - Hepatocellular Carcinoma, Hepatoma | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 43 | 2014-06-01 | 2019-01-16 |
| Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 1 | Withdrawn | Medical College of Wisconsin | 2012-06-01 | 2013-09-05 | |
| Sorafenib and TRC105 in Hepatocellular Cancer TRC 105, Sorafenib - Hepatoma, Liver Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-02-11 | 2019-01-23 |
| Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy Cinobufacin injection - Hepatoma, Cinobufacin Injection | Phase 2 | Unknown | Changhai Hospital | 284 | 2010-11-01 | 2011-06-28 |
| IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread Salmonella typhimurium - Cancer of the Liver, Liver Cancer | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 22 | 2010-04-01 | 2020-07-20 |
| A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol propranolol - Liver Cirrhosis, Hepatoma | Phase 4 | Unknown | Taipei Veterans General Hospital, Taiwan | 60 | 2009-10-01 | 2011-06-15 |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost - Hepatocellular Carcinoma, Hepatoma | Phase 1 | Terminated | Lisa H. Butterfield, Ph.D. | 2 | 2009-06-01 | 2015-12-03 |
| A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® TheraSphere® - Liver Tumors, Hepatocellular Carcinoma | Completed | St. Joseph Hospital of Orange | 18 | 2009-02-01 | 2021-04-06 | |
| Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma sorafenib, LC Bead-TACE - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Completed | Yale University | 50 | 2009-02-01 | 2021-11-11 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Hepatocellular (26) · Liver Neoplasms (12) · Neoplasms (3) · Cholangiocarcinoma (2) · Esophageal Neoplasms (2) · Glioma (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Adenoma, Liver Cell (1) · Biliary Tract Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Hepatitis C (1)
Adenocarcinoma (26) · Carcinoma (26) · Digestive System Diseases (26) · Digestive System Neoplasms (26) · Liver Diseases (26) · Neoplasms by Histologic Type (26) · Neoplasms by Site (26) · Neoplasms, Glandular and Epithelial (26) · Neoplasms (23) · Liver Neoplasms (14) · Adenoma (2) · Biliary Tract Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Esophageal Diseases (2)
Sorafenib (4) · Nivolumab (2) · Desflurane (1) · Immunotherapy, Adoptive (1) · Irinotecan (1) · ON 01910 (1) · Oxaliplatin (1) · Propranolol (1) · Radiotherapy (1) · Sevoflurane (1) · TKM-080301 (1) · carotuximab (1) · elbasvir-grazoprevir drug combination (1) · huachansu (1) · phosphomannopentaose sulfate (1)
Shenzhen BinDeBio Ltd. (2) · Arbutus Biopharma Corporation (1) · Asan Medical Center (1) · Bayside Health (1) · Boston Scientific Corporation (1) · Bristol-Myers Squibb (1) · Central Texas Veterans Health Care System (1) · Changhai Hospital (1) · Lisa H. Butterfield, Ph.D. (1) · Mahidol University (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1)
United States (14) · China (6) · Taiwan (4) · Singapore (3) · South Korea (3) · Canada (2) · Hong Kong (2) · Japan (2) · Spain (2) · Thailand (2) · Argentina (1) · Australia (1) · Brazil (1) · Chile (1) · Czechia (1)
Anastasia Becker (1) · Beth A. Erickson-Wittmann, M.D. (1) · Changhoon Yoo, MD, PhD (1) · Dionisios Vrochides, MD PhD (1) · Edward W. Greeno, MD (1) · James Pingpank, MD (1) · Karen T Brown, MD (1) · Kenneth Kolbeck, MD, PhD (1) · Koshi Makita, M.D. (1) · Lawrence Wagman, M.D., F.A.C.S. (1) · Mark Kowalski, M.D., Ph.D. (1) · Ming-Chih Hou, MD (1) · Pankaj Singh, MD (1)
PMID 17543307, PMID 18981929, PMID 26834067, PMID 27870743, PMID 30161292, PMID 30598500, PMID 30677524, PMID 31592509, PMID 31672606, PMID 38374347
2018 (1), R01CA104524 (1)